Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02957968
Title Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Virginia Commonwealth University

Her2-receptor negative breast cancer


Decitabine + Pembrolizumab

Cyclophosphamide + Doxorubicin

Carboplatin + Paclitaxel


Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
St. Elizabeth Healthcare Edgewood Kentucky 41017 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Virginia Charlottesville Virginia 22903 United States Details
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298 United States Details
VCU Community Memorial Healthcenter Richmond Virginia 23950 United States Details
*Shaded cells indicate that there was no data available from for the field